export@pu-kang.com            lorena@pu-kang.com
You are here: Home » News » Antibody-Drug Conjugates: The Last Decade

Antibody-Drug Conjugates: The Last Decade

Views: 0     Author: Nicolas Joubert; Alain Beck;Charles Dumontet;Caroline Denevault     Publish Time: 2021-11-05      Origin: National Library of Medicine


facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button
Antibody-Drug Conjugates: The Last Decade


An armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of.

Keywords: ADC; antibody–drug conjugate; bioconjugation; cancer; combination therapies; linker; payload; resistance.

Conflict of interest statement

Alain Beck is an employee of Pierre Fabre, Charles Dumontet has received research funding from Roche and is a founder of Mablinks. All authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

About Us
Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
Contact Us
​​​​​​​​​​​​​​No.288 of North Rongtai Avenue,WenJiang district 611137,Chengdu Sichuan
Copyright © 2021 chengdu Pukang Biological Technology Co., Ltd.  Support By Leadong  Sitemap / Private Policy
Leave a Message
Contact us